/
GLUE
$23.90+$1.61 (+7.22%)live
Held · Bookmarked
0 · 0
portfolios · users
Avg position size
—
of holders' portfolios
13F filers
1
institution
Market cap
$1.9B
84M shares
52-week range
$4.12 – $25.77
91% from low
Sector
BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)
Exchange
NASDAQ
CS
Borrow rate
0.29%
Easy to borrow
Price (6 mo)
Loading chart…
Change+$1.20
Valuation
Financials
Loading chart…
Click rows below (any statement) to add/remove series. Selection stays as you switch tabs.
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 | $0 | $75.6M | $123.7M |
| Cost of revenue | $72.0K | $537.0K | $0 | $0 | $6.2M | $8.1M | $8.4M |
| Gross profit | −$72.0K | −$537.0K | $0 | $0 | −$6.2M | $67.5M | $115.3M |
| Gross margin | — | — | — | — | — | 89.3% | 93.2% |
| R&D | $7.3M | $23.5M | $57.2M | $85.1M | $105.0M | $121.6M | $141.5M |
| Operating income | −$8.0M | −$28.0M | −$72.9M | −$112.4M | −$143.3M | −$81.1M | −$54.2M |
| EBITDA | −$7.7M | −$27.5M | −$71.8M | −$101.0M | −$128.8M | −$62.0M | −$31.4M |
| Net income | −$8.0M | −$35.9M | −$74.0M | −$108.5M | −$135.4M | −$72.7M | −$38.6M |
| Net margin | — | — | — | — | — | -96.1% | -31.2% |
| EPS (diluted) | -0.18 | -0.82 | -1.59 | -2.30 | -2.63 | -0.98 | -0.46 |
Annual figures · source: Financial Modeling Prep
Analyst estimates (consensus)
| Year | Est. revenue | Est. EPS | EPS range | # Analysts |
|---|---|---|---|---|
| 2026 | $44M | $-1.66 | $-2.52–$-0.32 | 5 |
| 2027 | $58M | $-1.84 | $-3.20–$0.62 | 5 |
| 2028 | $22M | $-2.29 | $-3.01–$-1.38 | 5 |
| 2029 | $115M | $-2.11 | $-6.61–$-0.07 | 1 |
Forward consensus · source: Financial Modeling Prep
DCF fair valuemodel estimate
Intrinsic value
$24.95
Price
$23.90
Implied upside
+4%
Peer comparison
Monte Rosa Therapeutics, Inc. Common Stock
Monte Rosa Therapeutics Inc is a clinical-stage biotechnology company that specializes in developing molecular glue degraders (MGDs), a class of small molecule drugs that leverage the body's natural protein destruction mechanisms to selectively degrade therapeutically-relevant proteins. Utilizing the QuEEN platform, the company employ artificial intelligence and proprietary experimental tools to identify target proteins for degradation by MGDs. The company has three programs in clinical development: MRT-6160, a VAV1-directed MGD for immune-mediated diseases; MRT-8102, a NEK7-directed MGD for inflammatory diseases driven by IL-6, and the NLRP3 inflammasome; and MRT-2359, a GSPT1-directed MGD for metastatic castration resistant prostate cancer (mCRPC).
www.monterosatx.com- Employees
- 161
- IPO / List date
- Jun 24, 2021
- HQ
- BOSTON, MA
Held by traders on TradeandTell
No one on the platform currently holds GLUE.
Super investors & insiders
Institutions holding (13F)
| Institution | Shares | Reported |
|---|---|---|
| Renaissance Technologiesas of 2026-03-31 | 379,100 | $6.2M |
Insider activity (SEC Form 4)
Recent trades on TradeandTell
No one on the platform has traded GLUE yet.
